• 9430 Key West Avenue Rockville, MD 20850 I (240) 268.1141

Cellphire Therapeutics Closes $3,000,000 Funding Round

June 30, 2017

Cellphire, Inc. announced today that it had closed a $3,000,000 funding round, with investments from both new investors and existing investors, management and the board of directors.  “The additional capital will augment the $69 million commitment from BARDA [the Biomedical Advanced Research and Development Authority],” said CEO Stephen Willard, “and enables us to initiate the commercial launch of our veterinary subsidiary BodeVet, Inc.”   BodeVet is expected to introduce its first commercial product, a freeze-dried canine platelet-derived hemostatic agent branded StablePlate RX™, at the International Veterinary Emergency and Critical Care Symposium in September 2017.

# # #

 About Cellphire, Inc. 

Cellphire, Inc. (www.cellphire.com) is working to solve the ubiquitous shortage of platelets for treatment of traumatic bleeding and other blood-related problems.  Platelets are critical to the body’s vascular system, responsible for the body’s ability to stop bleeding.  Unlike other blood products that can be frozen and stockpiled for use when needed, platelets must be stored at room temperature, and they spoil after just five days. Cellphire’s lead product, Thrombosomes®, a human platelet-derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a powder that can be stored for years, then reconstituted and brought back to life with sterilized water. Cellphire’s platform technology has tremendous potential across a wide range of medical applications from trauma to wound care, anti-coagulant reversal, imaging, targeted drug delivery and regenerative medicine.  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Thomas Dann
(240) 268-2489
tdann@cellphire.com

 

Source:  Cellphire, Inc.